The SARS-CoV-2 neutralising antibody profile of New Zealand adults in 2023: Impact of vaccination and infection

The successive dominance of SARS-CoV-2 omicron sublineages presents challenges for vaccination strategies with respect to the antigenic content of boosters. New Zealand's COVID-19 elimination strategy (2020−2021) ensured the major vaccination campaign (Pfizer-BioNTech BNT162b2) was completed pr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2024-12, Vol.42 (26), p.126482, Article 126482
Hauptverfasser:	McGregor, Reuben, Paterson, Aimee, Lavender, Brittany, Hooker, Caitlin, Frampton, Chris, Wiig, Kjesten, Le Gros, Graham, Ussher, James E., Brewerton, Maia, Moreland, Nicole J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies Antibodies, Neutralizing - blood Antibodies, Neutralizing - immunology Antibodies, Viral - blood Antibodies, Viral - immunology Antigens BNT162 Vaccine - administration & dosage BNT162 Vaccine - immunology Booster Cartography COVID-19 COVID-19 - epidemiology COVID-19 - immunology COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - immunology Ethnicity Female Humans immunity Immunity (Disease) Immunization, Secondary Infections Male Middle Aged Neutralising antibodies New Zealand New Zealand - epidemiology Omicron Population studies Sars-cov-2 SARS-CoV-2 - immunology Severe acute respiratory syndrome coronavirus 2 Vaccination Vaccines Variant Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!